ALBAWABA - The Food and Drug Administration (FDA), which is responsible for protecting public health by ensuring the safety, efficacy, and security of drugs, biological products, medical devices, the food supply, cosmetics, and radiation-emitting products, has announced plans to collaborate with OpenAI, the American artificial intelligence research organization, to evaluate drugs and medications using AI.
FDA collaborates with OpenAI
The FDA plans to collaborate with OpenAI with the aim of accelerating the drug development and evaluation process.
The project, cderGPT, is an artificial intelligence (AI) tool developed by the Center for Drug Evaluation and Research (CDER), which regulates prescription and over-the-counter drugs in the United States. Notably, partners from Elon Musk’s Drug Evaluation and Quality (DOGE) Center were also reportedly involved in the discussions.
The project, cderGPT, is an artificial intelligence (AI) tool developed by the Center for Drug Evaluation and Research (CDER), which regulates prescription and over-the-counter drugs in the United States. (Shutterstock)
As artificial intelligence (AI) becomes increasingly integrated into all aspects of our lives, the FDA and OpenAI aim to accelerate drug development and evaluation in the United States (US) and globally. Artificial Intelligence (AI) has the potential to streamline the drug development process, making it faster and more efficient.
However, experts are raising concerns about the reliability and oversight of artificial intelligence (AI) models, particularly in high-stakes areas such as medicine.
